For people diagnosed with macular telangiectasia type 2 (MacTel)—a rare and slowly progressing retinal disease—there have ...

Therefore, this investigation aimed to compare different treatment protocols mimicking chronic (i.e., 30 days) to­pical exposure to BAK at a concentration of 0.1% (approximately 13 times greater than ...

The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic ...